News
Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, ...
Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...
Viking Therapeutics (VKTX) stock drops as its oral obesity drug VK2735 trails Novo's (NVO) oral Wegovy and Lilly's (LLY) ...
Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.
Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.
Viking Therapeutics, Inc.'s VK2735 trial results disappointed, yet long-term potential in the obesity market makes the stock ...
Wegovy is now positioned as the first and only GLP-1 treatment.
Saxenda falls outside Medicare drug plan coverage because Medicare does not cover GLP-1 agonists when doctors prescribe them specifically for weight management.
Recent federal and state developments have shifted the ground under medispas. The US Food and Drug Administration (FDA) ...
Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for ...
While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...
Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results